Clinical trials: asthma
Asthma
Mass Balance Recovery, Pharmacokinetics and Metabolite Profile and Identification of [14C]AZD7594
AZD7594 is in clinical development for the treatment of asthma. This is a single centre, open-label, single period study in 6 healthy subjects, to determine the mass balance recovery and generate samples to enable metabolite…
- Trial name
- NCT04002427
- Testing
- Intravenous Infusion, Inhaled dose
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Allergic Rhinitis and/or Rhinoconjunctivitis +- Asthma, Immunotherapy, Allergen
Dose Finding Study for Depigoid Birch: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma
Specific immunotherapy for subcutaneous application: Dose finding study to evaluate the correct dose. 4 concentrations of a birch pollen allergen extract are applied in this study. Duration of therapy 20 weeks.
- Trial name
- NCT01144429
- Testing
- Allergoid, allergenic extract of 100% Birch
- Where
- 39 sites in Germany, Lithuania and 1 more
- Volunteers
- 344 people
- Sponsor
- Leti Pharma GmbH
Asthma
Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study in Healthy Subjects.
To evaluate the safety and tolerability of S-1226 composed of perflubron with ascending doses of carbon dioxide (4%, 8%, and 12% CO2) administered over 2 minute nebulisation to healthy subjects.
- Trial name
- NCT02616770
- Testing
- S1226 (4%), Saline (for 4%), S1226(8%)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- SolAeroMed Inc.
Asthma
Study of ARO-RAGE in Healthy Subjects
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-RAGE Injection in normal healthy volunteers.
- Trial name
- NCT05533294
- Testing
- ARO-RAGE Injection
- Where
- New Zealand
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Asthma
Neurostimulation for the Relief of Acute Bronchoconstriction
The goal of this study is to validate design for the Resolve™ Stimulator and Proximity Electrode and the associated procedure to quickly and safely place an electrode into the neck, in the vicinity of the vagus nerve by a…
- Trial name
- NCT00762931
- Testing
- Resolve Stimulator and Proximity Lead
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- ElectroCore INC
Asthma
An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients
This study is a multicenter, observational, prospective study to evaluate the asthma biologic use features and clinical outcomes in China.
- Trial name
- PRESENTII (NCT06605885)
- Where
- 29 sites in China
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)
This is a 3-week study to evaluate FEV1 following treatment with drugs in persistent asthma which is also active during allergy seasons in pediatric patients with seasonal aeroallergen sensitivity.
- Trial name
- NCT00289874
- Testing
- montelukast sodium
- Volunteers
- 421 people
- Sponsor
- Organon and Co
Asthma
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes that may Support Future Development of…
- Trial name
- NCT06419413
- Where
- 21 sites in China
- Volunteers
- 355 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers, Asthma
Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals
RP3128 is a calcium release activated calcium (CRAC) channel modulator. The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending dose(s) of RP3128 in healthy…
- Trial name
- NCT02958982
- Testing
- RP3128
- Where
- Canada
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Rhizen Pharmaceuticals SA
Asthma
Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment
The purpose of this study is to demonstrate substantial equivalence between two medical devices which measure nitric oxide in exhaled breath, NIOX MINO® and NIOX® in Symptomatic Asthmatic Adults and Children.
- Trial name
- eNOugh (NCT00388570)
- Testing
- The Aerocrine NIOX MINO® Airway Inflammation Monitor
- Where
- 2 sites in Sweden, United Kingdom
- Volunteers
- 151 people
- Sponsor
- Aerocrine AB
Asthma
To Assess the Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients With Asthma on Inhaled Corticosteroids
A Phase 1 study to assess pharmacokinetics (PK) and safety of abediterol 5 μg dry powder inhaler (DPI) given once daily (QD) for 9 days, compared to placebo, in patients with asthma on inhaled corticosteroids (ICSs).
- Trial name
- NCT03273127
- Testing
- Abediterol
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- AstraZeneca
Atopic Asthma
A Phase IIa Repeat Dose AXP1275 vs Placebo Cross-over Trial With Pulmonary Allergen Challenge in Adults With Asthma
This is the first study in human patients with asthma that the sponsor is conducting in order to evaluate if there are signals that the investigational medication, AXP1275, may be a safe and effective treatment for asthma.
- Trial name
- NCT01890161
- Testing
- AXP1275
- Where
- 3 sites in Canada
- Volunteers
- 21 people
- Sponsor
- Axikin Pharmaceuticals, Inc.
Asthma, COPD
Costs & Outcomes of Hospitalization/Treatment With Levalbuterol & Albuterol in Asthma or Chronic Obstructive Pulmonary Disease (COPD) Subjects
An analysis of the costs and outcomes associated with hospitalization and treatment of Levalbuterol versus Racemic Albuterol in subjects with Asthma and COPD.
- Trial name
- POLARIS (NCT00667797)
- Testing
- levalbuterol HCl, albuterol Sulfate
- Where
- 18 sites in United States
- Volunteers
- 486 people
- Sponsor
- Sumitomo Pharma America, Inc.
Asthma
Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics
The purpose of this study is to compare the test product Budesonide/formoterol Easyhaler with the marketed product Symbicort Turbohaler in terms of the drug absorbed into the bloodstream.
- Trial name
- KINECO (NCT00964535)
- Testing
- budesonide and formoterol 200/6 microg
- Where
- United Kingdom
- Volunteers
- 87 people
- Sponsor
- Orion Corporation, Orion Pharma
Asthma, Allergic
Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.
This is a multi-centre, randomized, double-blind，placebo parallel-controlled phase III study to evaluate the efficacy and safety of CMAB007 (recombinant humanized anti-immunoglobulin E(IgE) monoclonal antibody for injection) to…
- Trial name
- NCT03468790
- Testing
- CMAB007, Symbicort, Seretide
- Where
- 2 sites in China
- Volunteers
- 393 people
- Sponsor
- Shanghai Biomabs Pharmaceutical Co., Ltd.
Asthma
A Study of Xolair to Evaluate Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma
This study is a multicenter, prospective, observational cohort study of ~5000 Xolair-treated and ~2500 non-Xolair-treated patients with moderate to severe persistent asthma and a positive skin test or in vitro reactivity to an…
- Trial name
- NCT00252135
- Volunteers
- 8,023 people
- Sponsor
- Genentech, Inc.
Asthma Patients
A Single-Arm Phase Ic Clinical Study of XKH001 Injection in Patients With Allergic Asthma After Multiple Doses
This study is a single-arm, open-label clinical study. A total of 12 patients with allergic asthma are planned to be enrolled to receive XKH001 600 mg Q4W administration for the assessment of the safety, immunogenicity, PK, and…
- Trial name
- NCT07070297
- Testing
- XKH001 Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Zhejiang Kanova Biopharmaceutical Co., LTD
Asthma, Healthy Volunteers
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days
RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
- Trial name
- NCT02140320
- Testing
- RV1729 single dose, RV1729 14 day repeat dose, RV1729 28 day repeat dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Respivert Ltd
Asthma
The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma
Primary Objective: To assess the effect of dupilumab on lung inflammation and related changes in airway volumes detectable by functional respiratory imaging Secondary Objective: To evaluate the effect of dupilumab at Week 24 on…
- Trial name
- VESTIGE (NCT04400318)
- Testing
- Dupilumab
- Where
- 65 sites in United States, Bulgaria and 11 more
- Volunteers
- 109 people
- Sponsor
- Sanofi
Asthma
Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg, in…
- Trial name
- NCT03879837
- Testing
- Fluticasone propionate pressurized metered dose inhaler, Flovent HFA pressurized metered dose inhaler
- Where
- United States
- Volunteers
- 1,902 people
- Sponsor
- Actavis Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.